FDA Approves First Buprenorphine Implant To Treat Opioid Addiction

FDA approved the first buprenorphine implant, Probuphine, Thursday (May 26) designed to deliver constant low-level doses of the drug for six months in order to treat opioid dependence. Buprenorphine is used as a medication-assisted treatment (MAT) to treat opioid dependence, and the approval comes as expanding MAT is a priority for FDA and HHS in combating the opioid epidemic. "Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make new,...